Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy


  • Finding new pathways involved in the immune response against oncohematological diseases and infections susceptible to therapeutic intervention.
  • Study of therapeutic strategies in patients undergoing hematopoietic stem cell transplantation to optimize the graft-versus-disease effect.
  • Development of cell therapy for clinical and research purposes with application in medical and surgical specialties.
  • Implement the immunophenotypic diagnosis of hematological malignancies for the application of targeted therapies (individualized treatment) and the improvement of residual disease follow-up.
  •  Optimization of strategies in Transfusion Therapy.
  •  Integration of multidisciplinary teams in the management of fragile patients with hematological malignancies.
  •  Promote multidisciplinary teams for the prevention and management of long-term complications caused by current treatments.
  • Promote participation and encourage leadership in cooperative groups and national and international "real world evidence" registries.
  • Fundraising from public and private entities for the maintenance and growth of the group.


  • Study of the immune system in the response to pathogens in oncohematological diseases
  • Effect of the immune response against oncohaematological malignancies and its modulation by new drugs
  • Cell therapy in patients undergoing hematopoietic stem cell transplantation and non-neoplastic diseases
  • Study and prevention of cardiac dysfunction secondary to certain drugs
  • Search for predictors of response in myeloproliferative neoplasms
  • Clinical and biological characterization (lymph node and bone marrow) of chronic B lymphoproliferative syndromes.
  • Implement genetic diagnosis in the diagnosis of red series diseases to establish phenotype-genotype relationships.
  • Development of diagnostic algorithms with serological and genetic tests that facilitate the resolution of complex immunohematological problems in Transfusion Medicine
  • Study of the long-term side effects of conventional chemotherapy and new drugs


Department of Haematology, 8th Floor


Translational Hematology; Onchohematology; Immune reconstitution, Cell Therapy, Hematopoietic Progenitor Transplantation, Myeloproliferative Neoplasms, Lymphoproliferative Syndromes, Coagulopathies, Transfusion Therapy.